Back to Stakeholders
Categories

1 domain / 2 areas / 1 specialization

Psych Capital

Data updated

17 Hanover Square, London W1S 1HU, United Kingdom

Psych Capital is a public-market psychedelic investor and media platform built around the medical psychedelics sector. Public filings describe it as the first pure-play psychedelic company to list in London, with an early-stage investment strategy focused on building and growing businesses within psychedelic healthcare.

It matters in the psychedelic ecosystem because it combines market coverage, events, and capital allocation around the sector, rather than operating as a generalist fund. Public filings show it has invested in Awakn Life Sciences and has explored further early-stage opportunities in medical psychedelics.

Investor Context

Venture Capital

Investment Context

This stakeholder is listed as a Venture Capital Fund within Venture Capital. Its public geography context is global. Public stage signals include Seed, Series A/B, and Growth / Late Stage. Public focus areas include Drug Development.

Public Portfolio Examples

Psych Capital appears to orient around the intersection of psychedelic-sector intelligence and direct investment, using its PSYCH platform, reports, and symposium activity to source and support deal flow. Its public filings emphasize early-stage opportunities in medical psychedelics, with a focus on healthcare delivery frameworks and sector-building companies rather than a broad multi-sector mandate. The record also indicates exposure to psychedelic industry infrastructure and drug-development adjacencies, alongside an investment in Awakn Life Sciences.

Investor Type

Venture Capital Fund

Geographic Scope

Global

Psychedelic Focus

Explicit Psychedelic Focus

Engagement

Active

Investment Stage Focus

SeedSeries A/BGrowth / Late Stage

Investment Focus Areas

Drug Development

Investment Orientation

Engagement Status

Active

Investor Type

Venture Capital Fund

Investment Website

Recorded Investments

private investment - £300,000

Psych Capital disclosed purchasing shares in Awakn Life Sciences as part of its investment strategy.

Psych Capital Plc annual report for the year ended 30 April 2022

Quick Facts

Founded
2021
HQ
17 Hanover Square, London W1S 1HU, United Kingdom
Website
Visit